Heribert Hanscheid

Oberdürrbacher Str. 6
Wuerzburg, BY 97080, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 69 publications

177Lu-based radioligand therapy: A retrospective multicenter analysis to calculate the effective half-life and follow-up dose for the public.

177Lu-based radioligand therapy: A retrospective multicenter analysis to calculate the effective half-life and follow-up dose for the public.

Journal: Nuklearmedizin. Nuclear medicine
Published: January 29, 2026

Correction: 131I therapy for benign thyroid disease: flexible single-time-point dosimetry using population-based model selection with non-linear mixed-effects modelling.

Correction: 131I therapy for benign thyroid disease: flexible single-time-point dosimetry using population-based model selection with non-linear mixed-effects modelling.

Journal: EJNMMI physics
Published: December 10, 2025

The revised German guideline on the monitoring for intakes of radionuclides.

The revised German guideline on the monitoring for intakes of radionuclides.

Journal: Radiation and environmental biophysics
Published: July 29, 2025

131I therapy for benign thyroid disease: flexible single-time-point dosimetry using population-based model selection with non-linear mixed-effects modelling.

131I therapy for benign thyroid disease: flexible single-time-point dosimetry using population-based model selection with non-linear mixed-effects modelling.

Journal: EJNMMI physics
Published: June 03, 2025

SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors.

SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors.

Journal: European journal of nuclear medicine and molecular imaging
Published: March 11, 2025

The EANM guideline on radioiodine therapy of benign thyroid disease.

The EANM guideline on radioiodine therapy of benign thyroid disease.

Journal: European journal of nuclear medicine and molecular imaging
Published: March 22, 2023

CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors.

CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: January 17, 2023

Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma.

Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma.

Journal: European journal of nuclear medicine and molecular imaging
Published: November 01, 2022

Determinants of target absorbed dose in radionuclide therapy.

Determinants of target absorbed dose in radionuclide therapy.

Journal: Zeitschrift fur medizinische Physik
Published: July 27, 2022

C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma.

C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: March 29, 2022

CXCR4-targeted theranostics in oncology.

CXCR4-targeted theranostics in oncology.

Journal: European journal of nuclear medicine and molecular imaging
Published: March 23, 2022

Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma.

Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma.

Journal: The Journal of clinical endocrinology and metabolism
Published: September 24, 2021
Showing 1-12 of 69

Last Updated: 09/26/2026